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Abstract
Objectives Recently, recombinant human bone morphogenet-
ic protein 9 (rhBMP9) has been characterized as one of the
most osteogenic growth factors among the 15 human BMPs.
The aim of the present study was to investigate the effects of
rhBMP9 in comparison to the clinically utilized rhBMP2 on
in vitro cell behavior when combined with two bone graft
materials including demineralized freeze-dried bone allografts
(DFDBAs) and biphasic calcium phosphate (BCP).
Materials and methods The absorption and release kinetics of
rhBMPs fromDFDBA and BCPwere investigated by ELISA.
Moreover, murine bone stromal ST2 cell behavior was inves-
tigated on DFDBA or BCP seeded on (1) graft only, (2)
rhBMP2 (10 ng/ml), (3) rhBMP2 (100 ng/ml), (4) rhBMP9
(10 ng/ml), and (5) rhBMP9 (100 ng/ml). The effects of
rhBMPs on DFDBA and BCP were assessed for cell adhe-
sion, proliferation, and osteoblast differentiation by alkaline
phosphatase (ALP) activity, alizarin red staining, and real-
time PCR for genes encoding Runx2, ALP, and bone
sialoprotein (BSP).
Results While both BMPs were gradually released from
DFDBA and BCP over time, significantly higher adsorption
was observed on BCP when compared to DFDBA. Cell at-
tachment and proliferation was higher on BCP with little in-
fluence of either rhBMP2/9. Despite rhBMPs having relative-
ly no effect on cell attachment/proliferation, a pronounced and
marked effect was observed on osteoblast differentiation for
both rhBMP2/9. Interestingly, it was observed that rhBMP9
induced significantly higher ALP activity, alizarin red stain-
ing, and messenger RNA (mRNA) levels of ALP and BSP
when compared to rhBMP2. Our results also revealed higher
differentiation for rhBMP2/9 with BCP when compared to
DFDBA most likely as a result of higher growth factor
adsorption.
Conclusion While both rhBMP2/9 combined with DFDBA
or BCP induced osteoblast differentiation, rhBMP9 induced
greater osteoblast differentiation when compared to rhBMP2.
Clinical relevance rhBMP9 may be a recombinant growth
factor with higher potential to induce new bone formation
when compared to rhBMP2. Further in vivo studies are nec-
essary to characterize its regenerative potential in various an-
imal models.
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Introduction
Bone morphogenetic proteins (BMPs) were discovered over
40 years ago displaying great potential to act as potent growth
factors capable of facilitating bone induction [1–3].
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Recombinant human (rh) BMP2 has been FDA-approved for
the regeneration of various bone defects utilized in the fields
of orthopedic and oral maxillofacial surgery due to their
osteoinductive potential [4–6]. Despite its widespread use, it
is interesting to note that several comparative studies have
revealed in fact that BMP2 is not the most osteopromote
growth factor among the BMP family. About a decade ago,
it was reported in several adenovirus transfection experiments
(gene therapy) that specifically adBMP9 had greater osteo-
genic potential as assessed both in vitro and in vivo by means
of comparative studies of all known BMPs [7, 8].
BMP9 is predominantly expressed in the liver [9] yet
acts as a major modulator of osteogenesis playing impor-
tant roles in the cell commitment and differentiation of
mesenchymal stem cells [10, 11]. Until recently however,
the osteogenic potential of BMP9 had only been investi-
gated through a gene therapy approach by utilizing ade-
novirus transfection, an area of research still not ap-
proved by the FDA for clinical use. Recently, our group
investigated for the first time the recombinant human
growth factor BMP9 (rhBMP9) and demonstrated its
greater osteogenic properties when compared to
rhBMP2 when combined with either a xenograft bone
graft or collagen membrane [12, 13]. For a further un-
derstanding of the regenerative potential of rhBMP9 for
various bone tissue engineering applications, the aim of
future research is to further characterize the ability of
rhBMP9 to influence osteoblast behavior on other bone
biomaterials.
Bone grafts are commonly classified into four groups
including autografts, allografts, xenografts, and
alloplasts [14]. While autogenous bone has been char-
acterized as the gold standard for bone regeneration,
disadvantages including additional donor site morbidity,
limited available supply, additional surgical time, and
costs have also been reported necessitating alternatives
[15, 16]. Demineralized freeze-dried bone allografts
(DFDBAs) and synthetic biphasic calcium phosphate
(BCP) have been extensively utilized in regenerative
dentistry as they possess excellent osteoconductive po-
tential [14, 17–20]. Therefore, the aim of the present
study was to assess if specifically rhBMP9 could fur-
ther induce their ostepromotive potential by loading an
osteoinductive growth factor within their matrix. First,
the three-dimensional morphology of each bone graft
was investigated by scanning electron microscopy.
Thereafter, the ability for either rhBMP2 and rhBMP9
to adsorb to bone-grafting materials and be released
over time was investigated. Lastly, the effects of
rhBMP9 in combination with either DFDBA or BCP
were investigated on cell attachment, proliferation, and
differentiation toward bone-forming osteoblasts in com-
parison to rhBMP2.
Materials and methods
Regents and cell line
rhBMP2 and rhBMP9 (CHO cell-derived) were purchased
from R&D Systems Inc. (Minneapolis, MN). DFDBA (DBX
Demineralized Bone Matrix Mix; Synthes Inc., West Chester,
PA) and BCP (maxresorb® granules, 0.5–1.0 mm, S size;
Botiss AG, Berlin, Germany), which is composed by 60 %
hydroxyapatite (HA) and 40 % β-tricalcium phosphate (β-
TCP), were used in the present study. For all in vitro cell
experiments, the following six groups for each bone graft
material were assessed: (1) control tissue culture plastic, (2)
control bone graft only, (3) bone graft + rhBMP2 low (10 ng/
ml), (4) bone graft + rhBMP2 high (100 ng/ml), (5) bone graft
+ rhBMP9 low (10 ng/ml), and (6) bone graft + rhBMP9 high
(100 ng/ml). Undifferentiated mouse bone stromal cell line
ST2 was obtained from RIKEN Cell Bank (Tsukuba, Japan).
Cells were cultured in a humidified atmosphere at 37 °C in
growth medium consisting of DMEM (Gibco, Life
Technologies, Carlsbad, CA), 10 % fetal bovine serum
(FBS, Gibco), and antibiotics (Gibco). For in vitro cell exper-
iments, 10 mg of bone graft was placed at the bottom of 24-
well dishes and pre-coated with rhBMP2 or rhBMP9 in
DMEM for 5 min, followed by cell seeding without rinsing
unadsorbed proteins. Cells were seeded at a density of 10,000
cells in 24-well culture plates for cell adhesion and prolifera-
tion experiments and 50,000 cells per well in 24-well dishes
for real-time PCR, alkaline phosphatase (ALP) assay, and
alizarin red experiments. For experiments lasting longer than
5 days, medium was replaced twice weekly.
Scanning electron microscopy
Scanning electronmicroscopy (SEM)was utilized to study the
morphological features of both bone-grafting materials. Either
DFDBA or BCP granule samples were sputter coated by using
an ion coater device with 10 nm of gold and analyzed micro-
scopically by using a scanning electron microscope as previ-
ously described [21].
BMP2 and BMP9 adsorption and release kinetics
quantification with ELISA
To determine the quantity of rhBMP2 and rhBMP9 adsorption
to DFDBA or BCP, ELISA quantification assay was utilized.
Briefly, after the coating period, incubation of 100 ng/ml of
rhBMP2/9 onto DFDBA and BCP at 37 °C in a shaking in-
cubator, the remaining PBS solution, containing unattached
protein, was collected and quantified by an ELISA Duoset
kit for BMP2 (DY355, range = 46.90–3000 pg/ml, R&D
Systems) and BMP9 (DY3209, range = 15.60–1000 pg/ml,
R&D Systems). Of rhBMP2/9 in PBS without mixing with a
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biomaterial, 100 ng/ml was quantified by ELISA, and the
amount of each protein was considered as positive control
(total coated protein). Subtraction of total coated protein from
the amount of un-adsorbed protein was used to determine the
amount of adsorbed material to the surface of DFDBA and
BCP as previously described [22]. Furthermore, in order to
determine the quantity of rhBMP2/9 protein being released
from DFDBA and BCP over time, coated grafts were soaked
in 1 ml of PBS and samples were collected at various time
points including 15 min, 1 h, 8 h, 1, 3, and 10 days. All
samples were quantified in duplicate, and three independent
experiments were performed.
Cell adhesion and proliferation assay
ST2 cells were seeded in 24-well plates at a density of 10,000
cells per well either on (1) control tissue culture plastic, (2)
bone graft only, (3) bone graft + rhBMP2 low (10 ng/ml), (4)
bone graft + rhBMP2 high (100 ng/ml), (5) bone graft +
rhBMP9 low (10 ng/ml), and (6) bone graft + rhBMP9 high
(100 ng/ml). Cells were quantified using MTS assay
(Promega, Madison, WI) by using an ELx808 Absorbance
Reader (BIO-TEK, Winooski, VT) at 1, 3, and 5 days for cell
proliferation as previously described [].
Real-time PCR analysis
Total RNA was isolated by using High Pure RNA Isolation
Kit (Roche, Switzerland) at 3 and 14 days for osteoblast dif-
ferentiation markers. Primer and probe sequences for genes
encoding runt-related transcription factor 2 (Runx2), ALP,
bone sialoprotein (BSP), and glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) were fabricated with primer se-
quences according to Table 1. Real-time RT-PCR was per-
formed by using Roche Master Mix and quantified on an
Applied Biosystems 7500 Real-Time PCR Machine. A
Nanodrop 2000c (Thermo, Wilmington, DE) was used to
quantify total RNA levels. The ΔΔCt method was used to
calculate gene expression levels normalized to GAPDH
values and calibrated to control samples.
ALP activity assay
At 7 days, cells were quantified for alkaline phosphatase ex-
pression utilizing a cell imaging system as previously de-
scribed [13]. Alkaline phosphatase activity was monitored
by using leukocyte alkaline phosphatase kit (procedure no.
86, Sigma). ST2 cells were fixed by immersion in a citrate-
acetone-formaldehyde fixative solution for 5 min. Alkaline
dye mixture were prepared by mixing 1 ml sodium nitrite
solution and 1 ml of fast red violet alkaline solution dissolved
in 45 ml of distilled water and 1 ml of Naphtol AS-Bl alkaline
solution. Surfaces were then placed in alkaline dye mixture
solution for 20 min protected from light followed by rinsing in
deionized water. All images were captured on a Wild
H e e r b r u g g M40 0 ZOOM Mak r o s k o p (W ILD
HEERBRUGG, Heerbrugg, Switzerland) at the same magni-
fication and light intensity and imported into ImageJ software
(NIH, Bethesda, MD). Thresholding was used to generate
percent stained values for each field of view.
Mineralization assay
ST2 cells were seeded in 24-well plates at a density of 50,000
cells per well with either (1) control tissue culture plastic, (2)
bone graft only, (3) bone graft + rhBMP2 low (10 ng/ml), (4)
bone graft + rhBMP2 high (100 ng/ml), (5) bone graft +
rhBMP9 low (10 ng/ml), and (6) bone graft + rhBMP9 high
(100 ng/ml) in osteogenic differentiation medium (ODM),
which consisted of DMEM supplemented with 10 % FBS,
1 % antibiotics, 50 μg/ml ascorbic acid (Sigma, St. Louis,
MO), and 10 mM β-glycerophosphate (Sigma) to promote
osteoblast differentiation as previously described [23]. At
14 days post ST2 cell seeding, cells were fixed in 96 % etha-
nol for 15 min and stained with 0.2 % alizarin red solution
(Alizarin Red S, Sigma) in water (pH 6.4) at room temperature
for 1 h as previously described [13, 23]. All images were
captured, and the percentage of staining was evaluated in the
same manner as the ALP assay.
Statistical analysis
All experiments were performed in triplicate with three inde-
pendent experiments for each condition. Data were analyzed
for statistical significance by using one-way analysis of vari-
ance with Tukey test (*p values <0.05 was considered signif-
icant) by GraphPad Prism 6.0 software (GraphPad Software,
Inc., La Jolla, CA).
Table 1 PCR primers
for genes encoding














SEM surface characteristics and BMP2 and BMP9
adsorption and release kinetics quantification with ELISA
In a first experiment, the three-dimensional surface morphol-
ogy of DFDBA and BCP granules was investigated via SEM
(Fig. 1). DFDBA demonstrated quite smooth surfaces that
were devoid of any visible proteins on their surface (Fig. 1a,
c). The high-resolution SEM imaging demonstrated slightly
roughened surfaces (Fig. 1e). In contrast, numerous
macropores and micropores were found on the surface of
BCP grafting particles (Fig. 1b, d). The high-magnified
SEM images of BCP demonstrated an extremely rough sur-
face in surface nanotopographies (Fig. 1f). Thereafter, the po-
tential of DFDBA and BCP granules to absorb and release
BMP2 and BMP9 was analyzed via ELISA (Fig. 2). The total
amount of adsorbed protein of either BMP2 or BMP9 to both
bone-grafting materials revealed a near 80 % adsorption
(Fig. 2a, b). DFDBA loaded with rhBMP9 demonstrated
Fig. 1 SEM images of a, c, e
DFDBA and b, d, f BCP particles
at ×100, ×400, and ×1600
magnifications
Clin Oral Invest
lower adsorption potential around 70 % the starting working
concentration (Fig. 2b). Thereafter, it was found that the
amount of BMP2/9 was slowly and gradually released over
time from 15 min up to 10 days (Fig. 2a, b). First, it was
observed that rhBMP2 loaded onto BCP demonstrated signif-
icantly higher remaining growth factor on the surface at 8 h, 1,
3, and 10 days (Fig. 2a). A similar trend was also observed
with rhBMP9 where BCP demonstrated significantly and
markedly more BMP9 at 60 min, 8 h, 1, 3, and 10 days
(Fig. 2b). These results demonstrate that BCP significantly
increased BMP adsorption when compared to DFDBA from
8 h to 10 days for BMP2 and from 60 min up to 10 days for
BMP9 (Fig. 2).
Effects of rhBMP2 and rhBMP9 combined with DFDBA
and BCP on ST2 cell adhesion and proliferation
The effects of rhBMP2 and rhBMP9 combined with DFDBA
and BCP were investigated on ST2 cell adhesion at 8 h and
cell proliferation at 1, 3, and 5 days post seeding (Fig. 3).
DFDBA significantly decreased ST2 cell attachment when
compared to control tissue culture plastic at 8 h post cell
seeding (Fig. 3a). Significantly lower values were further ob-
served on DFDBA particles loaded with rhBMP2 high when
compared to control DFDBA (Fig. 3a), whereas no significant
differences between the other groups were observed (Fig. 3a).
On the other hand, BCP did not influence cell adhesion when
compared to control tissue culture plastic (Fig. 3b). A signif-
icant decrease in BCP particles loaded with rhBMP2 was ob-
served when compared to BCP particles loaded with rhBMP9
low (Fig. 3b).
DFDBA and BCP were then tested for their abilities to
induce cell proliferation (Fig. 3c, d). While DFDBA signifi-
cantly suppressed cell growth by roughly 50 % when com-
pared with control plastic at 1, 3, and 5 days post seeding, no
significant differences were observed among all groups seed-
ed on DFDBA (Fig. 3c). Cell growth on BCP significantly
decreased slightly when compared with control tissue culture
plastic at 1 and 5 days post cell seeding, while no significant
difference among all samples seeded on BCP at 1 and 5 days
(Fig. 3d). These results seem to point to the fact that cells
adhere and proliferate more favorably on BCP when com-
pared to DFDBA (Fig. 3).
Effects of rhBMP2 and rhBMP9 combined with DFDBA
and BCP on osteoblastic differentiation
We then investigated the osteogenic behavior of rhBMP2 and
9 when coated onto DFDBA and BCP particles utilizing ALP
activity staining (Fig. 4), real-time PCR (Fig. 5), and alizarin
red staining (Fig. 6). It was first observed that DFDBA itself
did not promote ALP activity when compared to control tissue
culture plastic (Fig. 4). Interestingly, however, DFDBA +
rhBMP9 high samples significantly increased a 7-fold in-
crease in ALP activity when compared with DFDBA only
(Fig. 4a, c). Moreover, all DFDBA samples significantly de-
creased Runx2 messenger RNA (mRNA) levels when com-
pared to control tissue plastic at 3 days post seeding (Fig. 5a),
while DFDBA + rhBMP2 high and DFDBA + rhBMP9 high
samples upregulated ALP mRNA levels up to 2-fold and BSP
mRNA levels up to 6-fold, respectively, at 14 days when com-
pared to control tissue culture plastic (Fig. 5c, e). Consistent
with previous findings, alizarin red staining demonstrated that
DFDBA + rhBMP2 high and DFDBA + rhBMP9 high sam-
ples significantly increased alizarin red staining at 14 days
post cell seeding when compared with control tissue culture
plastic (Fig. 6c).
In comparison, BCP + rhBMP9 demonstratedmuch greater
osteogenic behavior when compared to either BCP + BCP9 or
DFDBA (Figs. 4, 5, and 6). While it was found that BCP +
rhBMP2 high samples significantly increased a 10-fold in-
crease in ALP activity when compared to control tissue cul-
ture plastic, both BCP + rhBMP9 low and BCP + rhBMP9
high samples significantly promoted a 50-fold increase in
ALP activity at 7 days post seeding when compared to control
samples (Fig. 4b, d). Moreover, real-time PCR analysis dem-
onstrated that only BCP + rhBMP9 high samples significantly
upregulated ALPmRNA levels up to 2.5-fold when compared
to control tissue culture plastic, BCP alone, and BCP +
rhBMP2 low samples (Fig. 5d). In addition, BSP mRNA ex-
pression in the BCP + rhBMP9 high group was significantly
higher when compared to all the other modalities (Fig. 5f).
Once again, it was revealed that alizarin red staining demon-
strated that while rhBMP2 samples significantly increased
Fig. 2 BMP2 and BMP9 release kinetics from a DFDBA and b BCP
granules at 15 min, 1 h, 8 h, 24 h, 3 days, and 10 days after loading on
each bone graft granules
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alizarin red staining when compared with control samples,
BCP particles combined with rhBMP9 (low or high) demon-
strated marked and significantly higher increases in staining
intensity when compared to BCP particles combined with
rhBMP2 (Fig. 6b, d).
Discussion
In the present study, the osteopromotive potential of rhBMP9
combined with DFDBA and BCP was investigated in com-
parison to rhBMP2 in order to determine the ability for both
growth factors to influence in vitro osteoblast behavior.
DFDBA and BCP bone grafts were first investigated for their
potential suitability as carriers for rhBMP2 and rhBMP9
(Fig. 2). It was first found that the adsorption potential of
rhBMP2 and rhBMP9was superior with BCPwhen compared
to DFDBA (Fig. 2). One of the plausible explanations for this
variation may be due to the fact that the rougher surface to-
pography and numerous micropore structures present on the
surface of BCP could favor protein absorption, whereas
DFDBA possesses a relatively smooth surface [24].
Moreover, it was found that rhBMPs released from both
DFDBA and BCP continued gradually up to 10 days; howev-
er, BCP demonstrated significantly more BMP retention when
compared to DFDBA, which suggested that BCP contributed
to a more slow and gradual release of BMPs over time.
Thereafter, the cell behavior of progenitor cells was inves-
tigated in response to DFDBA and BCP loaded with either
rhBMP2 or rhBMP9. It was observed that DFDBA signifi-
cantly decreased ST2 cell attachment; however, BCP did not
negatively influence the attachment of cells to bone-grafting
particles when compared to control tissue culture plastic
(Fig. 3a, b). A similar trend was also observed for cell prolif-
eration where a significantly higher number of cells were
found at all time points on BCP particles when compared to
DFDBA (Fig. 3c, d). Interestingly, the addition of rhBMPs to
either DFDBA or BCP had relatively no effect on cell adhe-
sion or proliferation (Fig. 3). These findings are supported by
similar other studies reporting that DFDBA significantly de-
creased cell proliferation onmurinemyoblast C2C12 cells and
on sarcoma osteogenic SaOS-2 cells [25, 26]. Moreover, in
another study with BCP, it was reported that BCP had no
effect on cell proliferation when compared to control tissue
Fig. 3 Cell adhesion assay and proliferation assay of ST2 cells seeded on
bone-grafting particles combined with rhBMP2 and rhBMP9. a, b ST2
cell attachment and c, d proliferation on a, cDFDBAor b, dBCPwith (1)
control tissue culture plastic, (2) bone graft only, (3) rhBMP2 low (10 ng/
ml), (4) rhBMP2 high (100 ng/ml), (5) rhBMP9 low (10 ng/ml), and (6)
rhBMP9 high (100 ng/ml) at 8 h post cell seeding (cell attachment) and at
1, 3, and 5 days post cell seeding (cell proliferation). (*p < 0.05, signif-
icant difference; **p < 0.05, significantly higher than all other modalities;
#p < 0.05, significantly lower than all other modalities)
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culture plastic on rat primary osteoblasts at 3 days and on
rabbit bonemarrowmesenchymal stem cells at 1, 3, and 7 days
[27, 28]. In combination with the findings from our study, it
may thus be concluded that the mesenchymal lineage cells
found in these studies prefer the roughened surface found on
BCP scaffolds when compared to the smoother DFDBA sur-
face. Future research investigating the activated cell signaling
pathways following cell attachment could reveal future cues
as to why mesenchymal cells seem to favor BCP bone
particles.
Fig. 4 a, b Images and c, d quantified data of alkaline phosphatase
(ALP) staining of ST2 cells on a, c DFDBA or b, d BCP with (1) control
tissue culture plastic, (2) bone graft only, (3) rhBMP2 low (10 ng/ml), (4)
rhBMP2 high (100 ng/ml), (5) rhBMP9 low (10 ng/ml), and (6) rhBMP9
high (100 ng/ml) at 7 days post cell seeding. (*p < 0.05, significant
difference; **p < 0.05, significantly higher than all other treatment
modalities)
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Furthermore, the osteogenic potential of rhBMP2 and
rhBMP9 combined with either DFDBA or BCP was then
investigated on osteoblast differentiation. While both bone-
grafting material did not induce osteoblast differentiation
when compared to control tissue culture plastic, both high
concentrations of either rhBMP2 and rhBMP9 combined with
DFDBA increased ALP mRNA levels up to 2-fold, BSP
mRNA up to 6-fold, and enhanced alizarin red staining at
14 days post seeding when compared with control tissue cul-
ture plastic (Figs. 5c, e and 6c). A previous study reported that
DFDBA combined with rhBMP2 induced effective bone for-
mation capable of forming ectopic bone formation [29]. In the
present study, the combination of DFDBA with rhBMP9
showed comparable osteopromotive potential to rhBMP2
with only alizarin red staining being significantly higher for
rhBMP9 when compared to controls (Fig. 4c).
On the other hand, when rhBMP9 was combined with
BCP, a significant increase in osteogenic behavior even when
compared to rhBMP2 was observed in all assays investigating
osteoblast differentiation. Even low concentrations of
rhBMP9 (10 ng/ml) combined with BCP significantly pro-
moted further ALP activities and alizarin red staining when
compared with rhBMP2 high. The different responses of
rhBMP2 and rhBMP9may be attributed to the fact that protein
adsorption and activity is greatly influenced by protein con-
formation following adsorption. Furthermore, it remains un-
known what may affect the timing of growth factor release of
BMPs from the scaffold surface which might play a role on
Fig. 5 Real-time PCR of ST2
cells seeded on a, c, e DFDBA or
b, d, f BCP with (1) control tissue
culture plastic, (2) bone graft only,
(3) rhBMP2 low (10 ng/ml), (4)
rhBMP2 high (100 ng/ml), (5)
rhBMP9 low (10 ng/ml), and (6)
rhBMP9 high (100 ng/ml) for
genes encoding a, b Runx2, c, d
ALP, and e, f bone sialoprotein
(BSP) at 3 and 14 days post-
seeding (**p < 0.05, significantly
higher than all other treatment
modalities; *p < 0.05, significant
difference)
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osteoblast differentiation. Therefore, it remains to be investi-
gated what may cause variability in protein adsorption of
growth factors to bone-grafting materials and their relation-
ship with osteoblast differentiation. Furthermore, it is unclear
what factors induced the attractive osteogenic potential of
rhBMP9. Based on adenovirus experiments, it might be attrib-
uted to the differences of canonical BMP signaling pathways.
Both BMP2 and BMP9 have been shown to activate SMAD
Fig. 6 Alizarin red staining of ST2 cells on a, c DFDBA or b, d BCP
with (1) control tissue culture plastic, (2) bone graft only, (3) rhBMP2 low
(10 ng/ml), (4) rhBMP2 high (100 ng/ml), (5) rhBMP9 low (10 ng/ml),
and (6) rhBMP9 high (100 ng/ml) at 14 days post seeding. a, b Images of
alizarin red-stained calcium nodules and c, d quantified evaluation of
alizarin red staining. (*p < 0.05, significant difference)
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pathways through the phosphorylation of the transcription
factors Smad1/5/8 by type I receptors in mesenchymal osteo-
blast cells [30, 31]. BMP stimulation induces BMP antagonist
and noggin expression and inhibits BMP2 action; however,
SMAD phosphorylation by BMP9 was not inhibited by exog-
enous noggin [30, 32, 33]. Furthermore, BMP3, a known
inhibitor of BMP2-mediated osteogenesis, does not inhibit
BMP9-mediated bone formation [8]. Further research utiliz-
ing rhBMP9 would benefit our understanding on the differen-
tial mechanisms that regulate osteogenesis in both BMP2 ver-
sus BMP9.
In the present study, it was clearly observed that rhBMP2/9
adsorbed better to BCP scaffolds and this, in turn, provided
better cell behavior contributing to the differentiation of pro-
genitor cells into mature osteoblasts. While the present data
seems to favor the combination of growth factors with BCP
(especially rhBMP9) on murine osteoprogenitor cells, it re-
mains to be investigated what effect both these bone-grafting
materials may have in human osteoprogenitor cells.
Interestingly, Sreekumar et al. reported that rhBMP9 treatment
showed significantly increased osteogenic activity including
AP activity and Smad nuclear translocation when compared to
the two clinically used rhBMP2 and rhBMP7 on primary hu-
man osteoblasts from 110 donors [34]. Therefore, future
in vitro study on human cells and in vivo animal study are
necessary to further characterize the regeneration potential of
either bone graft when combined with rhBMP2 and rhBMP9.
Conclusion
The results from the present study demonstrate that both
rhBMP2 and rhBMP9 combined to DFDBA and BCP
displayed the potential to induce osteoblast differentiation.
Interestingly, rhBMP9 in combination with BCP demonstrat-
ed the greatest stimulation of osteoblasts favoring significant-
ly higher ALP activity, alizarin red staining, and expression of
osteoblast differentiation markers ALP and BSP. While the
results from the present study favors the use of rhBMP9 over
rhBMP2, further in vivo studies remain necessary to further
characterize the osteoinductive potential of rhBMP9 when
combined with either DFDBA or BCP for future clinical use.
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